A multicentre, randomised, double-blind, placebo-controlled study investigated the impact of granulocyte colony stimulating factor (G-CSF) as an adjunct to chemotherapy on infection incidence among patients with small-cell lung cancer [12]. This evidence concerns the gene CSF3 and infection.